EMA Application withdrawn: Iplex (mecasermin rinfabate) — Insmed Europe Ltd

View source ↗

Summary

The EMA application for Iplex (mecasermin rinfabate) by Insmed Europe Ltd has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dwarfism
• Pituitary Dwarfism

Drugs mentioned

• IPLEX (melanotropin? (note: IPLEX is a brand for hexastim? actually IPLEX is a recombinant human insulin-like growth factor? Wait))

Snippet

Status: Application withdrawn. Therapeutic area: Dwarfism, Pituitary. MAH: Insmed Europe Ltd. Decision date: 31/12/2009